Evidence map›Paper›PMID 32891174›Full record

ArticleJournal of nanobiotechnology2020

Topically applicated curcumin/gelatin-blended nanofibrous mat inhibits pancreatic adenocarcinoma by increasing ROS production and endoplasmic reticulum stress mediated apoptosis.

Tao Cheng, Zhiheng Zhang, Hua Shen, Ziying Jian, Junsheng Li, Yujun Chen, Yi Shen, Xinyi Dai

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Influence of3 Biotech · 2021
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Tao ChengDepartment of General Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210000, China.
Zhiheng ZhangDepartment of Surgery, Klinikum Rechts Der Isar, School of Medicine, Technical University of Munich, 81675, Munich, Germany.
Hua ShenDepartment of Plastic Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Ziying JianDepartment of Hematology and Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 21000, China.
Junsheng LiDepartment of General Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210000, China.
Yujun ChenBio-ID Center, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
Yi ShenBio-ID Center, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China. shenyi12@sjtu.edu.cn.ORCID http://orcid.org/0000-0002-1679-9238
Xinyi DaiDepartment of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, 200011, China. daixy1979@gmail.com.
Shanghai Jiao Tong University · CNZhongda Hospital Southeast University · CNTUM Klinikum · DE

Funding

CAS Key Laboratory of Interfacial Physics and Technology CASKL-IPT1702Fundamental Research Funds for the Central Universities 3290008413Fundamental Research Funds for the Central Universities 3290008414Science and Technology Commission of Shanghai Municipality 17JC1400804Science and Technology Commission of Shanghai Municipality 18142202100Science and Technology Commission of Shanghai Municipality 19PJ1408600
6 · The paper itself

Abstract

backgroundPancreatic adenocarcinoma (PDAC) is one of the most fatal malignancies. Surgical resection supplemented by chemotherapy remains the major therapeutic regimen, but with unavoidable resistance and systemic toxic reaction. Curcumin is a known safe natural compound that can effectively eliminate pancreatic adenocarcinoma cells in vitro, making it a promising candidate for substitution in subsequent chemotherapy. However, due to its extremely low bioavailability caused by its insolubility and circular elimination, curcumin had an unexpectedly modest therapeutic effect in clinical trials.

resultsHere, we electrospun curcumin/gelatin-blended nanofibrous mat to largely improve curcumin's bioavailability by local controlled-release. With characterization by scanning electron microscopy, fluorescence microscopy, Fourier transform infrared spectroscopy, X-ray diffraction and high-performance liquid chromatography, it was revealed that curcumin was uniformly dispersed in the fiber of the mats with nanoscopic dimensions and could be continuously released into the surrounding medium for days. The cancer inhibitory effects of nano-curcumin and underlying mechanisms were further explored by assays using pancreatic adenocarcinoma cell and experiments using xenograft model. The results showed the released nano-curcumin could effectively inhibit pancreatic adenocarcinoma cell proliferation not only in vitro, but more importantly in vivo. This cytotoxic effect of nano-curcumin against pancreatic adenocarcinoma was achieved through provoking the production of intracellular reactive oxygen species and activating endoplasmic reticulum stress, which leads to enhanced cell apoptosis via decreased phosphorylation of signal transducer and activator of transcription 3.

conclusionsClinically, curcumin/gelatin-blended nanofibrous mat could be a promising, secure, efficient and affordable substitutional agent for the elimination of residual cancer cells after tumor resection. Moreover, our strategy to obtain curcumin released from nanofibrous mat may provide a universally applicable approach for the study of the therapeutic effects and molecular mechanisms of other potential medicines with low bioavailability.

Indexed as

AdenocarcinomaAnimalsAntineoplastic AgentsApoptosisBiological AvailabilityCell Line, TumorCell ProliferationCurcuminEndoplasmic Reticulum StressGelatinHumansMiceNanofibersPancreatic NeoplasmsReactive Oxygen SpeciesXenograft Model Antitumor AssaysAntineoplastic AgentsCurcuminGelatinReactive Oxygen SpeciesBioavailabilityCurcuminNanofibrous mat (NM)Pancreatic adenocarcinomaTumor suppression

Identifiers

PMID32891174
PMCPMC7487882
OpenAlexW3083124959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.